Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00683878 · ClinicalTrials.gov registry record · Phase 3
Add-on to Thiazolidinedione (TZD) Failures
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 972
- Enrollment target
NCT00683878: Completed Phase 3 study, sponsored by AstraZeneca.
NCT00683878 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 972 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (26% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00683878, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 972 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in subjects with Type 2 Diabetes who are not well controlled on TZD alone. The safety of this treatment will also be studied
Primary Outcome
HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtai
Interventions
- DRUG Dapagliflozin
- DRUG Placebo matching Dapagliflozin
- DRUG Thiazolidinedione (Pioglitazone)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 972 participants |
| Start Date | 2008-07 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
What the finished NCT00683878 record still lists
NCT00683878 is an interventional study that assigns participants to a tested intervention. The registered 972 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (26% higher).
The record links to 0 conditions, and to 3 interventions - of which Dapagliflozin is the first listed.
NCT00683878 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00683878 about?
NCT00683878 is a clinical study titled "Add-on to Thiazolidinedione (TZD) Failures". The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in subjects with Type 2 Diabetes who are not well controlled on TZD alone. The safety of this treatment will also be studied
What is the current status of trial NCT00683878?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 972 participants. The study started on 2008-07. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00683878?
The interventions under investigation include: Dapagliflozin (DRUG), Placebo matching Dapagliflozin (DRUG), Thiazolidinedione (Pioglitazone) (DRUG).
Who is sponsoring clinical trial NCT00683878?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00683878's enrollment target sits among peer trials
972 329th of 2000 higher than 1,672 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06948422 · 974 participants · Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
- NCT05354141 · 970 participants · Phase 3
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
- NCT05600777 · 975 participants · Phase 3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- NCT06541704 · 975 participants · Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia